Overview

Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

To assess the safety of 48 weeks of treatment with 10 mg of elvucitabine in combination with background ART in subjects who completed protocol ACH443-014A and meet the inclusion and exclusion criteria.

Phase:

Phase 2

Details

Lead Sponsor:

Achillion Pharmaceuticals
Alexion Pharmaceuticals

Treatments:

Anti-Retroviral Agents
Dexelvucitabine
Emtricitabine
Lamivudine